Molecular Dx firm Biocartis raises $45M in Series D financing

12/16/2012 | Clinica (subscription required)

Biocartis has secured $45 million in a Series D funding round, which it aims to use to increase its menu of cancer assays that run on the Apollo molecular diagnostics system. The Apollo platform, which the Swiss company purchased from Philips two years ago, is set to be introduced in Europe next year.

View Full Article in:

Clinica (subscription required)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL